DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Clinical trials for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT trials appear
Sign up with your email to follow new studies for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for young brain cancer patients: enzyme therapy targets tumors
Disease control Not yet recruitingThis study tests a drug called ADI-PEG 20, which breaks down an amino acid that some brain tumors need to grow. It is given alongside standard radiation and chemotherapy to children, adolescents, and young adults with newly diagnosed high-grade glioma. The goal is to see if this …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1, PHASE2 • Sponsor: Sabine Mueller, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Nasal spray could deliver brain tumor treatment directly to Kids' tumors
Disease control Not yet recruitingThis early-phase trial tests a nasal spray called NEO100 (a purified natural compound) in 12 children with certain aggressive brain tumors. The goal is to see if it's safe, find the best dose, and check if the drug reaches the tumor. Participants will receive increasing doses, an…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC